Live prices from 5 SA suppliers, from R500.00, compared side by side so you never overpay.
Copy the code — you'll paste it at checkout.
with our exclusive code
You're about to visit an external supplier
with our exclusive code
By clicking "Continue", you acknowledge that you understand and accept the above. Read our full disclosure.
Compare 1 price for SLU-PP-332. Cheapest: R1,200.00. Average: R1,200.00.
| Compare | Visit | |||||||
|---|---|---|---|---|---|---|---|---|
Pure Peptides SA
Best
SLU-PP-332 6mg |
R1,200.00 | R200.00/mg | In Stock | R200.00 |
—
|
— |
More ways to compare SLU-PP-332
Different views of the same live SA pricing, tuned for how you like to shop.
Compare another peptide
All purchases are made directly from third-party suppliers; your relationship is solely with them. We accept no liability for the quality, purity, or legality of any products listed.
We may earn a commission when you click through to a supplier and make a purchase. This does not affect pricing information displayed.
By using this site you accept responsibility for ensuring purchases comply with applicable laws in your jurisdiction. Read our full disclosure.
Synthetic Pan-ERR Agonist | Exercise Mimetic & Metabolic Modulator
Groundbreaking synthetic compound from Saint Louis University functioning as pan-estrogen-related receptor agonist with preferential ERRα activity. Activates metabolic pathways engaged during physical exercise without physical activity requirement.
Binds and activates ERRα/β/γ which regulate energy metabolism gene expression. Upregulates PGC-1α (mitochondrial biogenesis master regulator), activates AMPK pathway, increases mitochondrial density to 1.8-fold, enhances oxidative phosphorylation and ATP production.
(E)-4-Hydroxy-N'-(naphthalen-2-ylmethylene)benzohydrazide
12% body weight reduction in 28 days without appetite suppression. Fat mass gain <0.5g vs ~5g controls.
Significantly improved glucose tolerance in obese mice with lower fasting glucose and insulin levels.
Increases resting energy expenditure by 25% for fatty acid oxidation within 2 hours.
Reduced hepatic steatosis, decreased hepatic triglycerides, and enhanced hepatic fatty acid oxidation.
70% increase in running time and 45% increase in running distance in preclinical models.
Increased type IIa oxidative skeletal muscle fibers with enhanced oxidative capacity.
Improved ejection fraction in heart failure models with reduced cardiac fibrosis.
First compound to reverse age-related mitochondrial dysfunction in 21-month-old mice.
Reversed age-related albuminuria increase and prevented podocyte loss in elderly mice.
Research compound - IP injection in animals only. No human administration protocols established.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Standard Metabolic Protocol | 50 mg/kg (animal dosing) | Twice daily | Intraperitoneal injection (IP) |
| Acute Exercise Enhancement | 50 mg/kg (animal dosing) | Single dose 1 hour pre-exercise | Intraperitoneal injection (IP) |
| Extended Treatment | 50 mg/kg (animal dosing) | Twice daily for 4-8 weeks | Intraperitoneal injection (IP) |
Both affect mitochondrial function and AMPK pathways - may have additive metabolic effects. Monitor blood glucose closely.
Enhanced insulin sensitivity may require significant dose reduction to prevent hypoglycemia.
Different mechanisms affecting weight loss and metabolism - combination could have additive effects.
Combining GLP-1 and ERR agonism may enhance metabolic effects - monitor weight loss rate closely.
Distinct mechanisms (ERR agonism vs NNMT inhibition) likely complementary without known interactions.
Complementary mitochondrial pathways - SLU-PP-332 increases biogenesis while NAD+ supports energy production.
GH optimization may complement metabolic enhancement for body composition without known interactions.
May preserve lean muscle during SLU-PP-332-induced fat loss through GH pathway.
Metabolic shift toward fat oxidation within 2 hours; gene expression changes at 3-6 hours; enhanced exercise performance 1 hour post-dose
Increased resting energy expenditure measurable; enhanced fatty acid oxidation by 25%; improved grip strength by day 6
Up to 12% weight loss by day 28; dramatic fat mass reduction; improved glucose tolerance; 45-70% endurance improvements; reduced hepatic steatosis
Cardiac improvements (ejection fraction, reduced fibrosis); age-related kidney dysfunction reversal; mitochondrial architecture restoration
Sustained anti-aging effects in aging studies; continued tissue mitochondrial improvement; duration after discontinuation unknown
Diet-induced obese mice, 50 mg/kg IP twice daily, 28 days: 12% body weight loss, 25% fatty acid oxidation increase, improved glucose tolerance, reduced hepatic steatosis.
Multiple mouse models, 50 mg/kg IP: 70% increase in running time, 45% increase in running distance, increased type IIa oxidative muscle fibers.
21-month-old mice, 8-week treatment: Reversed age-related kidney decline, reduced albuminuria, prevented podocyte loss, restored mitochondrial architecture.
Heart failure models, 6-week treatment: Improved ejection fraction, ameliorated cardiac fibrosis, improved survival, enhanced mitochondrial ultrastructure.
Plain-English guides and study summaries from published literature.
Be the first to know when prices drop on your favourite peptides
No spam. Unsubscribe anytime. We respect your privacy.
